Rachelmycin

Rachelmycin (CC-1065) is an antitumor antibiotic and a DNA-alkylating agent. Rachelmycin has cytotoxic potency that can be used as a cytotoxin to synthesis ADC. Rachelmycin effectively inhibits DNA synthesis. Rachelmycin can be used for cancer and infection research[1][2][3].

Deadly poison by intravenous andintraperitoneal routes. Mutation data reported. Whenheated to decomposition it emits toxic fumes of NOx.

[1] W C Krueger, et al. Calf Thymus DNA binding/bonding Properties of CC-1065 and Analogs as Related to Their Biological Activities and Toxicities. Chem Biol Interact. 1992 Mar;82(1):31-46. DOI:10.1016/0009-2797(92)90012-a
[2] Martin DG, et al. CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity. J Antibiot (Tokyo). 1981 Sep;34(9):1119-25. DOI:10.7164/antibiotics.34.1119
[3] Reynolds VL, et al. The chemistry, mechanism of action and biological properties of CC-1065, a potent antitumor antibiotic. J Antibiot (Tokyo). 1986 Mar;39(3):319-34. DOI:10.7164/antibiotics.39.319